Clinical Trials Browser

Interventional × Fallopian Tube Neoplasms × atezolizumab × Clear all

NCT02839707 2026-03-18

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT03206047 2025-03-13

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03363867 2023-08-07

BEACON

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03038100 2023-02-17

IMagyn050

Phase 3 Completed

1,301 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms